Ronald F. Tutrone Jr.

机构：Chesapeake Urology Associates · ORCID：0000-0001-6705-778X

发表论文 205 篇 · 总被引 3576 次 · h-index 29

代表论文

• Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study (2024 · European Urology · 被引 59)
• ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. (2024 · Journal of Clinical Oncology · 被引 48)
• Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (2025 · New England Journal of Medicine · 被引 42)
• Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial (2025 · Frontiers in Oncology · 被引 19)
• Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy (2024 · Journal of Nuclear Medicine · 被引 15)
• Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing (2024 · Prostate Cancer and Prostatic Diseases · 被引 8)